news

Our latest
Press Releases & Updates

Latest press releases

RetinAI will attend EURETINA 2022 from September 1st to 4th in Hamburg

RetinAI will attend the 22nd EURETINA Congress, from September 1st to 4th, at the CCH (Congress Centre Hamburg) in Hamburg, Germany. EURETINA 2022 attendees will get first-hand insights on the company’s two new products: Our new data management platform, Discovery CORE, designed to share data in a privacy-preserving and secure manner across a network of collaborators, fostering and facilitating knowledge network building, vendor-neutral collaborative data analysis & management, education, training and teleophthalmology. Our Disease Evaluation Apps on Heidelberg Engineering’s secure data workflow solution, called AppWay, for connecting to AI applications.

RetinAI attends OIS Retina Innovation Summit and ASRS 2022 Annual Meeting from July 13th to 16th in New York

RetinAI will attend the OIS Retina Innovation Summit on July 13th at the Edison Ballroom NYC, and the ASRS 2022 Annual Meeting, from July 14th to 16th, at the Javits Convention Center in New York. ASRS attendees who visit RetinAI at Booth #625 will benefit from learning and seeing live demos on RetinAIs latest products and services.

RetinAI announces multi-year software license and services agreement for RetinAI Discovery® UNITY platform

RetinAI announces a multi-year license and services agreement with Novartis AG (“Novartis”) for its Discovery® UNITY platform. Discovery UNITY is RetinAI’s top of the line enterprise-wide solution to aggregate imaging data for global organizations, including data from clinical and real-world evidence studies, with AI that can be applied to improve understanding of patient populations and outcomes at scale.

RetinAI receives FDA Clearance for Discovery, our medical image & data management platform for Ophthalmology

RetinAI today announces U.S. Food and Drug Administration (FDA) 510(k) clearance of RetinAI Discovery®, the company’s image and data management platform for next-level interoperability across the clinical and clinical study ecosystems in Ophthalmology.

Venture Kick Phase III [DECEMBER'17]

Early detection of eye diseases is key for effective treatment to reduce the onset of blindness. However, the patient’s journey to diagnosis is often long and involves many challenges. Venture Kick just awarded RetinAI with 130'000.- CHF to make eye care accessible and affordable to everyone via artificial intelligence.

Read more

5th Medtech & Digital Health Forum Basel [OCTOBER'17]

RetinAI participated in the latest edition of the 5th Medtech & Digital Health Forum in Basel. The team had the opportunity to present our current developments and efforts towards bringing Artificial Intelligence to Ophthalmology, specially in developing countries.

NVIDIA GTC Munich 2017 [OCTOBER'17]

RetinAI held a presentation during the last edition of the Nvidia GTC Europe in Munich, covering how ophthalmology is changing with Machine Learning. Stefanos Apostolopoulos (Technical Director) and Dr. Sandro De Zanet (Scientific Director) presented the efforts the company is doing to improve medical eye care around the world.

‍